— Know what they know.
Not Investment Advice

PTLF OTC

Petlife Pharmaceuticals, Inc.
1W: +0.0% 1M: +0.0% 3M: -50.0% YTD: +0.0% 1Y: +0.0% 3Y: -95.0% 5Y: -32.2%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 48 · $19675 mcap · 208M float · 0.0001% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.000099999997-0.0002
Volume500
Avg Volume104
Beta3.91
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOSebastian Serrell-Watts
Employees1
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2008-05-14
8033 Sunset Boulevard
Los Angeles, CA 90046
US
424-216-6807
About Petlife Pharmaceuticals, Inc.

Based in Los Angeles, California, Petlife Pharmaceuticals, Inc. is dedicated to the discovery, formulation, commercialization, and ongoing support of both medicinal drugs and nutritional supplements for pets. Their primary focus is on addressing canine and feline cancer and various autoimmune conditions, such as arthritis, within the United States market. The company's leading product is Vitalzul, which functions by obstructing the formation of new blood vessels crucial for the growth of solid tumors. Petlife is also progressing the development of Vitalzul into a potent, prescription-only oral medication, as well as a highly concentrated version for direct intravenous or injectable application to tumors. Additionally, their offerings extend to developing palatable treats suitable for dogs and cats.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms